Pursuits
Pfizer Deal Could Be Worth $187 Million for Allergan's Saunders
- Performance-based shares could be valued at about $44 million
- Deal faces regulatory hurdles from U.S. Treasury Department
Pfizer Said to Be Near Deal for Allergan
This article is for subscribers only.
Brent Saunders has a $187 million incentive to sell Allergan Plc, the company he’s run since July 2014, to Pfizer Inc. for $380 a share.
Saunders’s holdings in the Parsippany, New Jersey-based Botox maker would be worth about $23 million, according to data compiled by Bloomberg from the company’s filings. His options -- both unexercisable and exercisable -- would be valued at $97 million at the $380 price. He also has unvested restricted shares that would be worth about $23 million and performance-based shares that would be valued at about $44 million at their target.